Summary of Expertise, Experience and Affiliations and Interests for the Scientific Advisory Panel on Opioid Analgesic Abuse (SAP-OAA)

Purpose of the Summary

The following summarizes the information about expertise or experience, affiliations and interests relevant to the Scientific Advisory Panel on Opioid Analgesic Abuse (SAP-OAA) mandate declared by committee members. Health Canada considered these declarations as part of the selection process. The Health Products and Food Branch has made this summary available as part of its commitment to be transparent about the membership of its advisory bodies.

Assessment of affiliations and interests prior to each meeting

Prior to each committee meeting, Health Canada assesses members' affiliations and interests, including direct financial interests, as they may apply to agenda items for discussion. Depending on the nature of the member's affiliations or interests, the Chair of the committee in consultation with the members, may limit the participation of a member in the meeting or ask him/her to make a verbal statement of affiliations and interests at the beginning of the meeting. Members' affiliations and interests are reviewed on an annual basis and updated as required based on changes in the status of their affiliations and interests.

In accordance with the Health Products and Food Branch Review of Regulated Products: Policy on Public Input and Guidance on Advisory Bodies, a person with a direct financial interest in the outcome of a review of a regulated product may be a member of an advisory body whose broader mandate encompasses matters of policy, management, or program development. However, such a member would not be asked to participate in any discussion, formulation of advice, or recommendations to Health Canada relating to that review.

Indicated Sector/Perspective and Expertise/Experience

Sector/perspective:

- Health professional
- Research
- Academia
- Patient/Consumer

Expertise/experience:

- Pain management specialists
- Psychiatrists with expertise in drug abuse
- Experts involved in the development of National Opioid Use Guideline Group (NOUGG)
- Drug delivery/technology
- Epidemiology
- Provincial/Territorial representative
- Pharmacology
- Pain/addiction patient representative

1. Direct financial interests
    a. Current employment, investments in companies, partnerships, equity, royalties, joint ventures, trusts, real property, stocks, shares or bonds, with the regulated industry

2. Indirect financial interests
    a. Within the past five years, payment from regulated industry for work done or being done, including past employment, contracts or consulting; or financial support including research support, personal education grants, contributions, fellowships, sponsorships, and honoraria[1]
    b. Within the past five years, materials, discounted products, gifts, or other benefits, or attendance at meetings where all or part of the travel and accommodation costs were provided by the regulated industry[2]
    c. Within the last three years, grants or other funding from the regulated industry to any of the organizations where you are currently employed or participate in internal decision making[3]

3. Intellectual interests
    a. Within the last five years, any formal advice or opinion to industry, a government organization or a non-government organization on a matter of relevance to the SAP-OAA
    b. Within the last five years, any published or publicly stated point of view on issues of relevance to the SAP-OAA mandate
    c. Current professional or volunteer affiliations such as membership of professional societies, lobbying, public interest or advocacy groups, of relevance to the SAP-OAA

4. Other
    a. Any other affiliations and interests or potential circumstances that might give a well-informed member of the public reasonable grounds for concern regarding the integrity and objectivity of your participation

---

[1] other than from present employer

[2] other than from present employer, over $1,000

[3] "participate in internal decision making" means as a board member, or as an executive or non-executive director

Name and Indicated Sector/Perspective and *Expertise/Experience*		**Summary of Response**							
Edward Sellers, MD, PhD, FRCPC (Chair)	Academia *Abuse liability*	1a) No	2a) Yes	2b) No	2c) No	3a) No	3b) No	3c) No	4) No
		Comments: Past President of Decision Line Clinical Research and Kendle Early Stage. Independent consultant for US government and pharmaceutical companies, for which his time has been compensated.							
Nady El-Guebaly, MD, FRCPC	Academia, Health Professional *Psychiatry, addiction*	1a) No	2) No	2b) No	2c) Yes	3a) No	3b) Yes	3c) Yes	4a) No
		Comments: Is a Board member of the International Society of Addiction Medicine, which has received conference grants from an international company. Was the past President of the Canadian Psychiatric Association. Has made numerous publications in various scientific journals.							
Andrea Furlan, MD, PhD	Academia, Health Professional *Physiatry, epidemiology*	1a) No	2a) No	2b) No	2c) No	3a) Yes	3b) Yes	3c) No	4a) No
		Comments: Is a contracted member of the drug advisory committee of the Workplace Safety and Insurance Board (WSIB) since Jan 2008. Was contracted by a Non-Governmental Organization to review different drug formulations. Has received honoraria to write an expert opinion paper for the WSIB on opioid use. Has received grants from the Canadian Institutes of Health Research and the Ontario Alternative Funding Plan Innovation Fund to conduct research on opioids. Has made numerous publications in various scientific journals.							
Raimar Löbenberg, PhD	Academia *Drug Delivery Systems*	1a) Yes	2a) No	2b) Yes	2c) No	3a) Yes	3b) Yes	3c) No	4a) No
		Comments: Has a consulting company. Is a United States Pharmacopeia (USP) council expert, for which his travel expenses have been paid by the USP council. Is a member of the American Association of Pharmaceutical Scientists (AAPS) focus group, in which he gave scientific overview of the topic and participated in the panel discussion.							
William Pryse-Phillips, MD, FRCP	Academia *Neurology, pain*	1a) No	2a) No	2b) No	2c) No	3a) No	3b) No	3c) No	4a) No
		Comments: None							
Beth Sproule, Pharm.D	Academia *Pharmacy, psychopharmaco-logy*	1a) No	2a) No	2b) No	2c) Yes	3a) Yes	3b) No	3c) Yes	4a) No
		Comments: Is an employee of the Centre for Addiction and Mental health, which receives research support from pharmaceutical industry. Has published a situational analysis for Health Canada. Has made numerous publications in various scientific journals. Is a member of the Ontario Pharmacists' Association, the Canadian Pharmacists' Association, the Canadian Society of Hospital Pharmacists and the College on Problems of Drug Dependence.							